Karsten Voermann : Hi Steve! I think your question was around what’s baked into guidance versus not. In terms of what’s baked into guidance, I think everything through today effectively. So we’ve considered the competitive environment certainly and how that’s been evolving, which Doug will speak to a little bit further. We’ve also considered everything we know today about Medicaid and what each of the states are doing in terms of rolling folks off Medicaid. So again, we took all information that we had available to us and incorporated that in.
Doug Hirsch: Sure. Thank you, Karsten. I think as we mentioned previously on the call, I just want to really reiterate what we really view as our competition, which is the 70% of Americans who simply don’t know that prices vary. There’s such an incredible opportunity for us to continue to educate consumers and guide them to better outcomes. I also wonder, I just set the table here about our three core strengths, which is really the way we frame our competition, which is again, our multi PBM marketplace were the only ones at scale, which means we drive lower prices. Just one data point, we beat competitors 87% of the time at the top retailers of the 30 most prescribed drugs. Secondly, our breadth, where again GoodRx for virtually all medications.
Obviously generics which is our suite spot and increasingly our brand where we can save thousands of dollars. And lastly on reach, we’re good at exports at every pharmacy in America, pretty much over 70,000 pharmacies plus mail, and then we have that incredible NPS that we spoke to a few times. So again, that’s really the competition and our key strengths against potential competition. With regard to your questions about individual folks, you know look, we’ve seen a lot of press releases, and we know that Amazon has focused over the course of many years actually to really get into the space and try to drive change. We have seen no evidence of growth in volume, and we’ve seen no impact on our business. And I just want to be pretty clear about that.
This latest program is for a subset of drugs, but we don’t see it as necessarily more compelling than some of the previous offerings they had out there, and so we do not see any direct impact on our business.
Steve Valiquette: Got it. Okay, thanks.
Operator: Thank you. One moment for our next question. Will come from the line of Stephen Dishart with KeyBanc. Your line is open.
Unidentified Analyst: Hey guys! Could you provide some color on what you’re currently seeing with your Gold Subscribers activity? Thanks.
Karsten Voermann : Sure. Thanks for the question. This is Karsten speaking to this one again. So on Gold, we continue to see some churn post our price increase from last year. Of course, from an elasticity perspective, revenue is way up. So the reality of the revenue increasing as much as it did, indicates that as we expected, we have a largely inelastic offering in our subscriptions offering. In particular, if you remember, we have never done a price increase since the inception of our subscriptions offering, even though the reality is that we had added a significant amount of value over the years, including just by way of example, discounts and telehealth among other types of offerings. So, from those perspectives, we felt like it was the right time to be able to do the price increase.
